Covant Tx

Covant Therapeutics: Discovering first-and-best-in-class therapeutics through covalency

[Dan Nomura @DanNomura]

Happy to present our latest paper with @pottslab & @Amgen in @J_A_C_S by co-first authors @C_M_Zammit & Cory Nadel on the discovery of a direct-acting covalent destabilizing degrader of AR and the undruggable truncation variant of AR, AR-V7, in androgen-independent prostate cancer cells that acts through targeting an IDR C125. Thanks also to @TheMarkFdn! https://t.co/2sUmRmJdax

[Rapé Lab @RapeLab]

Kudos to @VividionRx for finding a small molecule activator of the KEAP1-CUL3 interaction. Really revealing that this interaction turned out to be rate-limiting for NRF2 degradation. Congratulations!

https://t.co/eQBbzh3BPE

[Dan Nomura @DanNomura]

New @biorxivpreprint from Gray lab @Stanford_ChEMH on covalent degraders based on SNaR chemistry to exploits DCAF16/11. https://t.co/N2Kjeid3Dp

[drug hunter @drughunter_com]

Vividion Continues to Teach Covalent Compounds New Tricks | https://t.co/hcTUn8y5yB

At the recent ACS Fall 2024 meeting, the structure and discovery story of Vividion's clinical oral covalent activator of KEAP1 were disclosed.

[Keith Hornberger @KRHornberger]

New MLKL degraders. Will note that the covalent handle abrogates potential turnover - these become stoichiometric. But still seem to degrade reasonably.
https://t.co/KU9bjQtxtu

[Covalent Modifiers @CovalentMod]

Aminomethyl Salicylaldehydes Lock onto a Surface Lysine by Forming an Extended Intramolecular Hydrogen Bond Network https://t.co/TyT2JIFs4o

[Covant Tx @CovantTx]

Come join our team of talented drug hunters to discover the next generation of #covalent #therapeutics https://t.co/9NG1UaexaA

[Covant Tx @CovantTx]

https://t.co/wtqP2qMABg

[Covant Tx @CovantTx]

Ligandability Assessment of IL-1β by Integrated Hit Identification Approaches - Covalent Drug Discovery is just warming up. https://t.co/1Kuz6VcRlp

[Covant Tx @CovantTx]

https://t.co/5WN6xpl8qY

[Covalent Modifiers @CovalentMod]

Reversible Covalent Inhibition─Desired Covalent Adduct Formation by Mass Action https://t.co/XaYuZDyfC1

[bioRxiv @biorxivpreprint]

Redirecting the pioneering function of FOXA1 with covalent small molecules https://t.co/KaAjnkY1GN #bioRxiv

[Guillaume Laconde @Glaconde34]

Structure-Guided Design and Optimization of Covalent VHL-Targeted Sulfonyl Fluoride PROTACs | Journal of Medicinal Chemistry https://t.co/MPGb3LuVQg

[Roivant Sciences @Roivant]

Watch CEO @gline reflect on Telavant #success, Immunovant's FcRn program, and our best-in-class pipeline with @BiotechTVHQ and @bradloncar! #biotech #innovation

[Covant Tx @CovantTx]

A new paper from Dylan Dieters-Castator describing the workflow development of a sensitive and robust N-Glycoproteomics workflow to enrich cell surface proteins. Congrats Dylan! https://t.co/BnlzTSGvmH

[Covant Tx @CovantTx]

https://t.co/qM8Rzj0rdH

[Covant Tx @CovantTx]

Design and Evaluation of PROTACs Targeting Acyl Protein Thioesterase 1 - Carvalho - ChemBioChem - Wiley Online Library https://t.co/qnmysuSmOF

[ACS Central Science @ACSCentSci]

A designed peptide selectively reacts with a single lysine residue on Nck, disrupts phase-separated signaling coacervates, shuts down an intracellular signal, & inhibits E. coli infection

NEW #ASAP by Jiang Xia, Chunjian Wu & team #CUHK
Read it here: https://t.co/PQPvGKG967

[Bruce Booth @LifeSciVC]

$XBI has just witnessed the best 2-month stretch EVER for the sector

It has seen 8 consecutive weeks of gains, up +14% in Nov and +18% more in Dec, or 39% off the Oct lows.

Fed rates, M&A boom, good data, cash recycling - all conspiring.

thx to Jack Bannister at Leerink

[Covant Tx @CovantTx]

Using a Function-First “Scout Fragment”-Based Approach to Develop Allosteric Covalent Inhibitors of Conformationally Dynamic Helicase Mechanoenzymes | Journal of the American Chemical Society https://t.co/soow7jqfxS